Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
65 hedge funds and large institutions have $95.3M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
10% more funds holding
Funds holding: 59 → 65 (+6)
8% more capital invested
Capital invested by funds: $87.9M → $95.3M (+$7.39M)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less call options, than puts
Call options by funds: $389K | Put options by funds: $451K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.66M |
| 2 |
Morgan Stanley
New York
|
+$4.47M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.19M |
| 4 |
DA
DSC Advisors
Chicago,
Illinois
|
+$961K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$537K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.03M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.8M |
| 3 |
DAM
DLD Asset Management
New York
|
-$1.6M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.51M |
| 5 |
Millennium Management
New York
|
-$1.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Barclays
London,
United Kingdom
| – | -$3.46K | -1,088 | -97% |
|
FOMX Hedge Fund Activity: Q4 2019 in Review
65 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2019, worth a combined $95.3M — up 8.4% from $87.9M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new FOMX positions and 11 closed out — a net gain of 6 holders — while 18 added to existing stakes and 17 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $5.66M. The largest seller was OrbiMed, cutting an estimated $7.03M.
- 65 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2019, up from 59 in Q3 2019.
- Funds reported $95.3M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2019, up 8.4% quarter-over-quarter.
- 17 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2019 and 11 closed out, a net change of +6 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2019 was Mangrove Partners, an estimated $5.66M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2019 was OrbiMed, an estimated $7.03M sold.
Based on aggregated 13F filings for Q4 2019.